Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study

EBioMedicine

Volumn 2, Issue 4, 2015, Pages 317-323

  Yoshino, Takayuki ^a   Muro, Kei ^b   Yamaguchi, Kensei ^c   Nishina, Tomohiro ^d   Denda, Tadamichi ^e   Kudo, Toshihiro ^f   Okamoto, Wataru ^g   Taniguchi, Hiroya ^b   Akagi, Kiwamu ^c   Kajiwara, Takeshi ^d   Hironaka, Shuichi ^e   Satoh, Taroh ^f  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b AICHI CANCER CENTER HOSPITAL   (Japan)

^c SAITAMA CANCER CENTER   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

^e CHIBA CANCER CENTER   (Japan)

^f OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g NATIONAL CANCER CENTER   (Japan)

Author keywords

Anti EGFR antibody treatment; Biomarker; Colorectal cancer; In vitro diagnostics; RAS mutation; RASKET study

Indexed keywords

GENOMIC DNA; DIAGNOSTIC KIT; KRAS PROTEIN, HUMAN; PROTEIN P21;

ARTICLE; CLINICAL TRIAL; CODON; COLORECTAL CANCER; DIAGNOSTIC ACCURACY; DNA EXTRACTION; EXON; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLEX POLYMERASE CHAIN REACTION; ONCOGENE RAS; PRIORITY JOURNAL; PROSPECTIVE STUDY; BIOASSAY; COLORECTAL TUMOR; DIAGNOSTIC KIT; DNA MUTATIONAL ANALYSIS; GENETICS; GENOTYPING TECHNIQUE; MULTICENTER STUDY; MUTATION; MUTATION RATE; STANDARD; VALIDATION STUDY;

COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; ENDPOINT DETERMINATION; EXONS; GENOTYPING TECHNIQUES; HUMANS; MUTATION; MUTATION RATE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS P21(RAS); REAGENT KITS, DIAGNOSTIC; REFERENCE STANDARDS;

EID: 84949673483     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.02.007     Document Type: Article

References (28)

1. Amado R.G., Wolf M., Peeters M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 2008, 26:1626-1634.
2. Bando H., Yoshino T., Tsuchihara K., et al. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br. J. Cancer 2011, 105:403-406.
3. Bando H., Yoshino T., Shinozaki E., et al. Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit. BMC Cancer 2013, 13:405.
4. Bokemeyer C., Bondarenko I., Makhson A., et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 2009, 27:663-671.
5. Didelot A., Le Corre D., Luscan A., et al. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Exp. Mol. Pathol. 2012, 92:275-280.
6. Diehl F., Schmidt K., Choti M.A., et al. Circulating mutant DNA to assess tumor dynamics. Nat. Med. 2008, 14:985-990.
7. Domagała P., Hybiak J., Sulz yc-Bielicka V., Cybulski C., Ryś J., Domagała W. KRAS mutation testing in colorectal cancer as an example of the pathologist's role in personalized targeted therapy: a practical approach. Pol. J. Pathol. 2012, 63:145-164.
8. Douillard J.Y., Siena S., Cassidy J., et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 2010, 28:4697-4705.
9. Douillard J.Y., Oliner K.S., Siena S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013, 369:1023-1034.
10. Fukushima Y., Yanaka S., Murakami K., et al. High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer. Gan To Kagaku Ryoho 2011, 38:1825-1835.
11. Gilbert M.T., Haselkorn T., Bunce M., et al. The isolation of nucleic acids from fixed, paraffin-embedded tissues-which methods are useful when?. PLoS One 2007, 2:e537.
12. Heinemann V., von Weikersthal L.F., Decker T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15:1065-1075.
13. Itoh Y., Mizuki N., Shimada T., et al. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 2005, 57:717-729.
14. Kawamoto Y., Tsuchihara K., Yoshino T., et al. KRAS mutations in primary tumours and post-FOLFOX metastatic lesions in cases of colorectal cancer. Br. J. Cancer 2012, 107:340-344.
15. Laurent-Puig P., Pekin D., Normand C., et al. Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res. 2014, 10.1158/1078-0432.CCR-14-0983.
16. Lièvre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006, 66:3992-3995.
17. Massarelli E., Varella-Garcia M., Tang X., et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin. Cancer Res. 2007, 13:2890-2896.
18. Maughan T.S., Adams R.A., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011, 377:2103-2114.
19. Normanno N., Tejpar S., Morgillo F., et al. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat. Rev. Clin. Oncol. 2009, 6:519-527.
20. Ozaki S., Kato K., Abe Y., et al. Analytical performance of newly developed multiplex human papillomavirus genotyping assay using Luminex xMAP™ technology (Mebgen™ HPV Kit). J. Virol. Methods 2014, 204:73-80.
21. Parsons B.L., Myers M.B. Personalized cancer treatment and the myth of KRAS wild-type colon tumors. Discov. Med. 2013, 15:259-267.
22. Parsons B.L., Marchant-Miros K.E., Delongchamp R.R., et al. ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. Cancer Investig. 2011, 28:364-375.
23. Prior I.A., Lewis P.D., Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012, 72:2457-2467.
24. Schwartzberg L.S., Rivera F., Karthaus M., et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 2014, 32:2240-2247.
25. Shinozaki E., Miki Y., Ueno M., et al. Molecular profiling of EGFR pathway according to location of colorectal cancer (CRC): analysis of 1,001 patients in single institute. J. Clin. Oncol. 2014, 32(Suppl.):3597. (abstract).
26. Smith G., Bounds R., Wolf H., Steele R.J., Carey F.A., Wolf C.R. Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine. Br. J. Cancer 2010, 102:693-703.
27. Van Cutsem E., Köhne C.H., Hitre E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N. Engl. J. Med. 2009, 360:1408-1417.
28. Watanabe T., Yoshino T., Uetake H., et al. KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. Jpn. J. Clin. Oncol. 2013, 43:706-712.